Preclinical Efficacy Evaluation of Antipsoriatic Drugs Targeting IL-17
Interleukin-17 (IL-17) plays a central role in psoriasis pathogenesis by driving keratinocyte hyperproliferation, amplifying inflammatory cascades, and sustaining chronic immune activation. Our preclinical evaluation platform provides robust, translational models to assess the therapeutic potential of IL-17-targeting drug candidates.
Download
This poster by Ace Therapeutics introduces a comprehensive preclinical evaluation platform for assessing the efficacy of antipsoriatic drug candidates targeting IL-17.
Our Capabilities
- Custom psoriasis models: Including IMQ-induced, IL-23-induced, and spontaneous mouse models mimicking IL-17-driven inflammation.
- Therapeutic modalities: Antibodies, inhibitors, small molecules, and novel biologics.
- Study designs tailored to the IL-17 pathway: Dosing strategies, topical or systemic delivery routes, and drug efficacy evaluation.
Key Readouts
- Scoring: Erythema, scaling, and thickness scoring aligned with PASI-like parameters.
- Histopathology: Epidermal thickness, parakeratosis, immune-cell infiltration.
- Cytokine and signal pathway analysis: IL-17A/F, IL-23, TNF-α, IL-22, and downstream signaling markers.
- Immunophenotyping: Quantification of Th17 cells, neutrophils, macrophages, and DC subsets.
Why Choose Us?
- Comprehensive service workflow: From model selection and study planning to endpoint analysis.
- Fast turnaround & flexible customization: Efficient project setup and tailored protocols for diverse therapeutic modalities.
